Eli Lilly pharmaceuticals news

On Dec. 20, 2012, Eli Lilly said it agreed to pay $29.4 million to settle issues regarding compliance with the U.S. Foreign Corrupt Practices Act (FCPA). The settlement relates to an investigation by the SEC of activities of four Lilly affiliates in Brazil, China, Poland and Russia from 1994-2009, including improper payments to government officials or third-party entities associated with government officials. The company said it believes the civil settlement, which also includes a 60-day review by an independent compliance consultant of the company's internal controls and compliance program related to the FCPA, resolves the issues. ...